These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12596997)

  • 1. Dual vector expansion of the recombinant AAV packaging capacity.
    Duan D; Yue Y; Engelhardt JF
    Methods Mol Biol; 2003; 219():29-51. PubMed ID: 12596997
    [No Abstract]   [Full Text] [Related]  

  • 2. Trans-splicing vectors expand the packaging limits of adeno-associated virus for gene therapy applications.
    Duan D; Yue Y; Yan Z; Engelhardt JF
    Methods Mol Med; 2003; 76():287-307. PubMed ID: 12526170
    [No Abstract]   [Full Text] [Related]  

  • 3. Expressing Transgenes That Exceed the Packaging Capacity of Adeno-Associated Virus Capsids.
    Chamberlain K; Riyad JM; Weber T
    Hum Gene Ther Methods; 2016 Feb; 27(1):1-12. PubMed ID: 26757051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel tools for production and purification of recombinant adenoassociated virus vectors.
    Grimm D; Kern A; Rittner K; Kleinschmidt JA
    Hum Gene Ther; 1998 Dec; 9(18):2745-60. PubMed ID: 9874273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and optimization of adeno-associated virus vector transfer into the central nervous system.
    During MJ; Young D; Baer K; Lawlor P; Klugmann M
    Methods Mol Med; 2003; 76():221-36. PubMed ID: 12526166
    [No Abstract]   [Full Text] [Related]  

  • 6. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus.
    Dong JY; Fan PD; Frizzell RA
    Hum Gene Ther; 1996 Nov; 7(17):2101-12. PubMed ID: 8934224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted integration by adeno-associated virus.
    Weitzman MD; Young SM; Cathomen T; Samulski RJ
    Methods Mol Med; 2003; 76():201-19. PubMed ID: 12526165
    [No Abstract]   [Full Text] [Related]  

  • 8. Adeno-associated virus-based vectors in gene therapy.
    Tal J
    J Biomed Sci; 2000; 7(4):279-91. PubMed ID: 10895050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison.
    Duan D; Yue Y; Engelhardt JF
    Mol Ther; 2001 Oct; 4(4):383-91. PubMed ID: 11592843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Site-specific integration of an adeno-associated virus vector plasmid mediated by regulated expression of rep based on Cre-loxP recombination.
    Satoh W; Hirai Y; Tamayose K; Shimada T
    J Virol; 2000 Nov; 74(22):10631-8. PubMed ID: 11044107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AAV as a viral vector for human gene therapy. Generation of recombinant virus.
    Rolling F; Samulski RJ
    Mol Biotechnol; 1995 Feb; 3(1):9-15. PubMed ID: 7606507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant AAV-mediated gene delivery using dual vector heterodimerization.
    Yan Z; Ritchie TC; Duan D; Engelhardt JF
    Methods Enzymol; 2002; 346():334-57. PubMed ID: 11883078
    [No Abstract]   [Full Text] [Related]  

  • 13. AAV6 Vector Production and Purification for Muscle Gene Therapy.
    Halbert CL; Allen JM; Chamberlain JS
    Methods Mol Biol; 2018; 1687():257-266. PubMed ID: 29067669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of packaging of adeno-associated virus gene therapy vectors using plasmid transfections.
    Chirico J; Trempe JP
    J Virol Methods; 1998 Dec; 76(1-2):31-41. PubMed ID: 9923737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene transfer into hepatocytes mediated by helper virus-free HSV/AAV hybrid vectors.
    Fraefel C; Jacoby DR; Lage C; Hilderbrand H; Chou JY; Alt FW; Breakefield XO; Majzoub JA
    Mol Med; 1997 Dec; 3(12):813-25. PubMed ID: 9440115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of packaging cell lines for generation of adeno-associated virus vectors by lentiviral gene transfer of trans-complementary components.
    Nakamura S; Nakamura R; Shibata K; Kobayashi M; Sahara N; Shigeno K; Shinjo K; Naito K; Ohnishi K; Kasahara N; Iwaki Y
    Eur J Haematol; 2004 Oct; 73(4):285-94. PubMed ID: 15347316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential use of cellular promoter(s) to target RPE in AAV-mediated delivery. Cellular promoters and RPE-targeting.
    Sutanto EN; Zhang D; Lai YK; Shen WY; Rakoczy PE
    Adv Exp Med Biol; 2006; 572():267-73. PubMed ID: 17249583
    [No Abstract]   [Full Text] [Related]  

  • 18. Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo.
    Gao G; Qu G; Burnham MS; Huang J; Chirmule N; Joshi B; Yu QC; Marsh JA; Conceicao CM; Wilson JM
    Hum Gene Ther; 2000 Oct; 11(15):2079-91. PubMed ID: 11044910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel tools for production and purification of recombinant adeno-associated viral vectors.
    Harris JD; Beattie SG; Dickson JG
    Methods Mol Med; 2003; 76():255-67. PubMed ID: 12526168
    [No Abstract]   [Full Text] [Related]  

  • 20. Small and Micro-Scale Recombinant Adeno-Associated Virus Production and Purification for Ocular Gene Therapy Applications.
    Reid CA; Lipinski DM
    Methods Mol Biol; 2018; 1715():19-31. PubMed ID: 29188503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.